Download Citation
Article Source:
A Phase I Randomized Placebo Controlled Trial of the Safety of 3% SPL7013 Gel (VivaGel®) in Healthy Young Women Administered Twice Daily for 14 Days
Cohen CR,
Brown J,
Moscicki AB,
Bukusi EA,
Paull JRA,
et al.
(2011)
A Phase I Randomized Placebo Controlled Trial of the Safety of 3% SPL7013 Gel (VivaGel®) in Healthy Young Women Administered Twice Daily for 14 Days.
PLOS ONE 6(1): e16258.
https://doi.org/10.1371/journal.pone.0016258